Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06430437 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

StatusRecruiting
PhasePhase 3
Started2024-07-29
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 21, 2026 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-01-18
Study Status, Arms and Interventions v2
InterventionsCamrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin (Drug), SHR-A1811 (Drug)→PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin (Drug), SHR-A1811 (Drug)
2025-02-21
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-08→confirmed 2024-07-29
Study sitesdetails revised at 1 of 1 site
2024-05-24
Original filing
The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 versus Standard of Care as first-line treatment of advanced or metastatic Non-Small Cell Lung Cancer with HER2- Mutations
Trial Details
NCT Number NCT06430437
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Non-Small Cell Lung Cancer With HER2- Mutations
Enrollment 300 participants
Start Date 2024-07-29
Primary Completion 2026-02 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-21